Loading…

Baxter InternationalBAXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Diversified medical device/supplies company focused on IV solutions/infusion systems, surgical/acute care products and injectable pharmaceuticals.

Momentum leader 84
Mkt cap
$13.5B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$178M
20-day average traded
Fwd P/E
12.7×
forward earnings
ROIC−WACC
-3.0 pp
WACC 7.4%
Hurdle
+14 pp
Req g minus delivered
Official | Implied
BBB- / BBB-
agencies · bond market
Next earnings
92 days
18 Feb 2027
Close · USD$26.16
1D+1.6%
1W-0.7%
1M+6.7%
3M-0.9%
6M+39.4%
YTD+37.0%
1Y+47.4%
ATR %3.6%
Beta1.04
52w lowhigh12.8% off high

What Baxter International does

Diversified medical device/supplies company focused on IV solutions/infusion systems, surgical/acute care products and injectable pharmaceuticals.

Hospitals buy IV solutions, pumps and consumables under multi-year supply contracts, so the installed pumps pull through recurring sales of tubing and fluids. In 2025 it sold most of its kidney-care business to Carlyle as Vantive, keeping a minority stake, after selling its biopharma contract-manufacturing unit in 2023.

Products and services

  • Medication Delivery (IV solutions/pumps)
  • Pharmaceuticals (injectables)
  • Surgical care/acute therapies
  • Retained Vantive kidney-care stake

Customers

  • Hospitals
  • Home care patients

Where it sits in the supply chain

  • Healthcare
  • Medical devices/supplies
  • IV therapy, surgical/acute care…

What could go right

  • Post-divestiture balance-sheet deleveraging
  • Acute-care/IV volume growth

What could go wrong

  • Product recall/quality issues
  • Debt load from portfolio restructuring

Moat: narrow (installed base, switching costs, scale). Broad installed base of IV/infusion equipment and long-standing hospital supply relationships.

Headquarters: Deerfield, Illinois, USA · Founded: 1931 · Employees: 37,500

Named competitors

Baxter International at a glance

Size Baxter International (BAX) is a United States Health Care company (Medical Specialties) with a market value of $13.5B, the 641st largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.16 on 18 Nov 2026.

Performance Over six months the shares gained 39.4%, against +25.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 5.3% over the last twelve months (peer median +5.9%); the operating margin is 5.9% (peer median 16.4%).

Valuation It trades at 12.7× forward earnings against a peer median of 20.0× (2nd cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.0 points below its cost of capital (7.4% WACC).

Backlog Backlog (remaining performance obligations) was $7.58B at 30 Sep 2026, down 23% on a year earlier — 0.7 years of trailing revenue. Backlog detail →

Credit Baxter International has 12 bonds outstanding ($8.28B), rated BBB- by the agencies and trading like BBB- at a weighted spread of 115 bp.

Short interest Short interest is 4.6% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026BAX 138Peer median 124
Six months, rebased to 100: Baxter International against the median of its 20 peers (local-currency closes).

Baxter International financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$11.6B$11.2B$10.6B$10.4B$14.5B
Revenue growth—+6%+3%-29%—
Gross profit$3.71B$3.71B$3.85B$3.99B$5.53B
EBITDA$1.64B$1.67B$1.68B$1.89B$3.02B
Net income-$705M-$1.05B-$649M-$226M-$2.43B
Free cash flow$1.14B$332M$573M$1.29B$591M
Capital expenditure$506M$522M$446M$432M$620M
Total debt$8.01B$9.78B$13.4B$14.1B$17.2B

Quarterly statements and history in the cockpit →

Baxter International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%LENSKARTGKOS6882717733PENSNBIMALGNCOOCOLO-BRVTYAVTRDEMANTQGENBIOPODDBRKRZBHGMEDGHBAX6-month return →1-month return →
Up and to the right = strong over both horizons. Baxter International is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×LENSKARTGKOS6882717733PENSNBIMALGNCOLO-BRVTYDEMANTBIOPODDGMEDBAXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Baxter International is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%LENSKART7733PENSNBIMCOOCOLO-BRVTYAVTRDEMANTQGENBIOPODDBRKRGMEDBAXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Baxter International is the large dot.

Baxter International competitors and peer comparison

Head to head with its named competitors (BAX vs FMS vs BDX vs ICUI)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%
Fresenius Medical Care AG Sponsored ADR FMS$11.6B-6%+4%11%9.2×-3.3%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
ICU Medical ICUI$4.46B+38%-6%8%19.4×18.9%
Fresenius SE & Co. KGaA FRE.DE$32.7B+41%+7%10%14.7×7.0%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Hikma Pharmaceuticals HIK.L$4.58B+15%+2%20%9.8×2.0%
Teleflex TFX$6.58B+23%-29%12%16.7×16.5%

How Baxter International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Baxter International against its 20 peers (data as of 18 Nov 2026)
MeasureBAXPeer medianRank in peer set
1-month return+6.7%+4.2%6th highest of 21
6-month return+39.4%+25.3%8th highest of 21
Distance from 52-week high-12.8%-15.2%10th highest of 21
Revenue growth (TTM)+5.3%+5.9%11th highest of 21
Operating margin5.9%16.4%3rd lowest of 21
Forward P/E12.7×20.0×2nd cheapest of 20
Growth the price implies (Req g, 7 yrs)13.4%10.6%7th most demanding of 18
Growth delivered (Del g)-0.7%+8.3%2nd lowest of 18
Hurdle (Req g minus delivered)+14.1 pp+4.2 pp5th most demanding of 18
ROIC minus cost of capital-3.0 pp+0.9 pp7th lowest of 21
EV / EBITDA11.9×14.0×9th cheapest of 18
Net debt / EBITDA3.7×1.1×most indebted of 18
Bond spread115 bp106 bp2nd widest of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a

Baxter International bonds and credit

Baxter International has 12 bonds outstanding with $8.28B face value. The agencies rate it BBB-; its bonds trade like BBB-. Weighted yield 5.71%, a spread of 115 bp over government bonds.

Every bond, yield and spread in the cockpit →

Baxter International backlog

Baxter International reported $7.58B of remaining performance obligations at 30 Sep 2026, down 23% from a year earlier and down 4% from the previous quarter. That is 0.7 years of trailing revenue already under contract. Book-to-bill last quarter: 0.89.

Questions

Who are Baxter International's main competitors?
Named competitors: Fresenius Medical Care (FMS), Becton Dickinson (BDX), ICU Medical (ICUI), Fresenius (FRE.DE), Pfizer (PFE), Hikma Pharmaceuticals (HIK.L). The cockpit's measured peer set (industry) also includes Lenskart Solutions (LENSKART.NS), Glaukos (GKOS), Shanghai United Imaging Healthcare (688271.SS), Olympus (7733.T), Penumbra (PEN), Smith & Nephew (SN..L).
Is Baxter International expensive compared with its peers?
On forward p/e it trades at 12.7× against a peer median of 20.0×, 2nd cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Baxter International stock performed?
Over six months to 18 Nov 2026 the shares returned +39.4% against +25.3% for the median peer; over one year +47.4%.
What is Baxter International's backlog?
Baxter International's remaining performance obligations (contracted revenue not yet recognised) were $7.58B at 30 Sep 2026, -23% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.